Skip to main
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 27%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Bausch & Lomb has demonstrated strong financial performance in 3Q25, achieving revenue growth across all three segments: Vision Care saw an 8% year-over-year increase with $736 million in revenue, Surgical grew 4% to $215 million, and Pharmaceuticals also rose by 8% to $330 million. Notably, the company is experiencing significant product-specific growth, exemplified by MIEBO's impressive 110% year-over-year prescription growth, which positions it to potentially surpass XIIDRA in the dry eye market by the end of 2025. Furthermore, management has provided positive guidance for 2025, indicating that the company is regaining momentum after its spin-off and continuing to improve its financial outlook despite a net loss of $28 million in the latest quarter.

Bears say

Bausch & Lomb faces significant challenges in maintaining its competitive position in the ophthalmology market, hampered by intense competition and promotional sensitivity among customers. The company's growth prospects appear limited due to a constrained product pipeline and high leverage following its acquisition of Xiidra, which could hinder future mergers and acquisitions necessary for expansion. Additionally, macroeconomic pressures and uncertainty surrounding elective procedures, along with risks tied to potential litigation with its former parent company, contribute to a negative outlook for the firm’s stock performance.

BLCO has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 27% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Buy based on their latest research and market trends.

According to 11 analysts, BLCO has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.